Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Commercial Officer | May 02, 2024 | May 06, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 02, 2024 · Filed May 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,767 |
Ending reported balance
After 2024-05-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-30 · Grant · Acquired 300 · Balance 71,767 F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Row 2 · 2024-05-02 · Sale · Disposed 5,000 · Balance 66,767 F2: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
F2: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,277 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 4,277 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2018 Filed Nov 17, 2018 00:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 799 | $93.81 | $74,957.31 |
DisclosureSEC source: 0001567619-18-006564 · doc1.xml · nonDerivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,735 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F4 · price: The price in column 4 is the weighted average price. The price actually received ranged from $93.12 to $94.09. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,400 | $92.21 | $221,296.80 |
DisclosureSEC source: 0001567619-18-006564 · doc1.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,534 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $92.01 to $92.95. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,201 | $91.62 | $476,493.78 |
DisclosureSEC source: 0001567619-18-006564 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,934 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $91.01 to $92.00. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 9,000 | $63.10 | $567,900.00 |
DisclosureSEC source: 0001567619-18-006564 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 22:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,000 | $98.98 | $98,984.80 |
DisclosureSEC source: 0001567619-18-003780 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,135 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $98.76 to $99.18. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052907 · doc4.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052907 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 23:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,750 | $56.76 | $383,130.00 |
DisclosureSEC source: 0001209191-18-051998 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $56.24 to $57.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 22:49 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,436 | $90.31 | $129,685.16 |
DisclosureSEC source: 0001140361-18-028475 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,135 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,414 | $92.07 | $130,186.98 |
DisclosureSEC source: 0001140361-18-027601 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,571 F1 · balance_after: Amount of securities beneficially owned has been adjusted from the reporting person's prior report to: a) add 86 shares reported as acquired in the Form 4 Amendment filed with the S.E.C. on 4/26/2018; and b) subtract 15 shares reported as disposed of in the Form 4 Amendment filed with the S.E.C. on 4/27/2018. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 309 | $85.96 | $26,561.64 |
DisclosureSEC source: 0001140361-18-022619 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,914 F2 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. Read SEC document |
| April 30, 2018 Filed May 9, 2018 22:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 309 | $68.78 | $21,253.64 |
DisclosureSEC source: 0001140361-18-022619 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,223 F1 · date: Represents shares acquired by the reporting person on April 30, 2018, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,119 | $80.12 | $169,774.28 |
DisclosureSEC source: 0001140361-18-016894 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,914 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. Read SEC document |
| March 29, 2018 Filed Mar 31, 2018 00:03 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,537 | $79.69 | $122,483.53 |
DisclosureSEC source: 0001140361-18-016271 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,033 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 23:36 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,583 | $81.36 | $291,512.88 |
DisclosureSEC source: 0001140361-18-015063 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,570 Read SEC document |
| March 22, 2018 Filed Apr 27, 2018 22:08 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,598 | $81.36 | $292,733.28 |
DisclosureSEC source: 0001140361-18-020267 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,555 F1 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of shares reported as forfeited. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 20:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,368 | $83.90 | $366,475.20 |
DisclosureSEC source: 0001140361-18-014807 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,153 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 41,040 | $0.00 Strike: $83.57 | $0.00 |
DisclosureSEC source: 0001140361-18-014186 · doc1.xml · derivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,040 Underlying: Common Stock · 41,040 shares Expires 2028-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-014186 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,521 F1 · price: Restricted stock units granted on March 15, 2018. Price not applicable. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,651 | $83.57 | $305,114.07 |
DisclosureSEC source: 0001140361-18-014186 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,681 Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 00:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,972 | $82.39 | $244,863.08 |
DisclosureSEC source: 0001140361-18-013341 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,332 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 01:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,614 | $79.86 | $128,894.04 |
DisclosureSEC source: 0001140361-18-012362 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,304 Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 01:52 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-010991 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,918 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F4 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 555 shares inadvertently included in prior reports based on a reconciliation with the Company's records. Read SEC document |
| February 26, 2018 Filed Apr 27, 2018 00:55 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-019870 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,004 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F4 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of RSUs reported as earned. F5 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 555 shares inadvertently included in prior reports based on a reconciliation with the Company's records. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,166 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001140361-17-036526 · doc1.xml · derivative · entry 6 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,166 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. F3 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,355 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001140361-17-036526 · doc1.xml · derivative · entry 5 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166 Underlying: Common Stock · 1,355 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. F3 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,166 | $95.00 | $205,770.00 |
DisclosureSEC source: 0001140361-17-036526 · doc1.xml · nonDerivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,944 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. F2 · price: All shares were sold at the same price. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,166 | $37.46 | $81,138.36 |
DisclosureSEC source: 0001140361-17-036526 · doc1.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,355 | $95.00 | $128,725.00 |
DisclosureSEC source: 0001140361-17-036526 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,944 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. F2 · price: All shares were sold at the same price. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,355 | $37.46 | $50,758.30 |
DisclosureSEC source: 0001140361-17-036526 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 6, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 21:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-17-053626 · doc4.xml · derivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2025-09-18 F5 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 21:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 33,750 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-17-053626 · doc4.xml · derivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires 2025-09-18 F4 · derivative.exercise_date: This stock option vests in equal monthly installments over the three-year period beginning on September 30, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 21:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053626 · doc4.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F3 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 19, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 21:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053626 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests over three years in equal annual installments beginning on September 19, 2017. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,004 | $89.61 | $89,968.44 |
DisclosureSEC source: 0001140361-17-024611 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,944 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F1 · deemedExecutionDate: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F2 · price: All shares sold at the same price. Read SEC document |
| June 02, 2017 Filed Jun 7, 2017 00:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,488 | $90.72 | $134,991.36 |
DisclosureSEC source: 0001140361-17-024244 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,948 Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,096 | $91.50 | $100,284.00 |
DisclosureSEC source: 0001140361-17-021235 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,436 Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,498 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-17-019043 · doc1.xml · derivative · entry 6 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,498 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F3 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 988 | $0.00 Strike: $28.23 | $0.00 |
DisclosureSEC source: 0001140361-17-019043 · doc1.xml · derivative · entry 5 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 988 shares Expires 2021-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F3 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,498 | $99.00 | $346,302.00 |
DisclosureSEC source: 0001140361-17-019043 · doc1.xml · nonDerivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,532 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,498 | $38.59 | $134,987.82 |
DisclosureSEC source: 0001140361-17-019043 · doc1.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 988 | $99.00 | $97,812.00 |
DisclosureSEC source: 0001140361-17-019043 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,532 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 988 | $28.23 | $27,891.24 |
DisclosureSEC source: 0001140361-17-019043 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. Read SEC document |
| May 02, 2017 Filed May 5, 2017 00:54 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 302 | $96.74 | $29,215.48 |
DisclosureSEC source: 0001140361-17-018529 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,532 F2 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F3 · price: All shares were sold at the same price. Read SEC document |
| April 28, 2017 Filed May 5, 2017 00:54 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 302 | $70.30 | $21,231.81 |
DisclosureSEC source: 0001140361-17-018529 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,834 F1 · date: Represents shares acquired by the reporting person pursuant to the issuer's Employee Stock Purchase Plan Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 21:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,890 | $89.15 | $346,793.50 |
DisclosureSEC source: 0001140361-17-014215 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,532 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 39,480 | $0.00 Strike: $87.42 | $0.00 |
DisclosureSEC source: 0001140361-17-013317 · doc1.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,480 Underlying: Common Stock · 39,480 shares Expires 2027-03-21 F2 · derivative.exercise_date: Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-013317 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,422 F1 · price: Restricted stock units granted on March 22, 2017. Price not applicable. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:36 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,288 | $92.50 | $304,140.00 |
DisclosureSEC source: 0001140361-17-012655 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,222 Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 00:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $90.56 | $452,800.00 |
DisclosureSEC source: 0001140361-17-011081 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,510 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 18, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.